TP53 and cancer: Restoring the expression of wild-type p53 in cancer cells would result in molecular changes with a particular signature, including the upregulation of genes transactivated by p53, such as p21, MIC-1, PUMA, BAX, BID, BAK, and NOXA, which can be used as therapeutic biomarkers of successful p53 stabilization [81,86,87].